Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus dexamethasone implant for macular edema after branch retinal vein occlusion
2011-001019-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in branch retinal vein occlusion (BRVO), macular edema and eye abnormalities comparing Lucentis arm with Ozurdex arm (2 arms). Primary endpoints: Change in best-corrected visual acuity from baseline to Month 6 and Safety. Started Apr 2011; status: completed.
02
Drugs
ranibizumabozurdex
03
Conditions
branch retinal vein occlusion (BRVO)macular edemaeye abnormalities
Beyond the preview
Go deeper on 2011-001019-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001019-30.